• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

How To Avoid China ’ s Medicine Monopoly
I want to share a shocking statistic with you… Around 80% of all the pharmaceuticals sold in America — both prescription and over-the-counter — are manufactured in China. I’m talking about drugs for Parkinson’s and Alzheimer’s, blood pressure and blood thinners, diuretics, aspirin, antibiotics, and a big chunk of the world’s insulin and diabetes drugs — just to name a few.1 We don’t even make penicillin anymore. The last penicillin plant in the U.S. closed its doors in 2004. Americans who rely on medicine are now almost entirely at the mercy of a country whose relations with the U.S. have become more ...
Source: Al Sears, MD Natural Remedies - September 19, 2023 Category: Complementary Medicine Authors: Jacob Tags: Health Source Type: news

Synthesis and biological evaluation of resveratrol amide derivatives as selective COX-2 inhibitors
Chem Biol Interact. 2023 May 11:110522. doi: 10.1016/j.cbi.2023.110522. Online ahead of print.ABSTRACTSelective COX-2 inhibitors have been considered to be reliable alternatives to tNSAIDs, but most of them were withdrawn from the market due to their risk of heart attack and stroke. Therefore, it is urgent to develop a new type of selective COX-2 inhibitor with high efficiency and low toxicity. Inspired by the cardiovascular protection, and anti-inflammatory activity of resveratrol, we synthesized 38 resveratrol amide derivatives and evaluated their COX-1/COX-2 inhibitory activities. Compounds 8a, 6a, 8c and 13c showed imp...
Source: Chemico-Biological Interactions - May 13, 2023 Category: Molecular Biology Authors: Min Xin Haoyu Wu Yuan Du Sheng Liu Feng Zhao Xiaofeng Mou Source Type: research

Aspirin and other non-steroidal anti-inflammatory drugs for the prevention of dementia.
CONCLUSIONS: There is no evidence to support the use of low-dose aspirin or other NSAIDs of any class (celecoxib, rofecoxib or naproxen) for the prevention of dementia, but there was evidence of harm. Although there were limitations in the available evidence, it seems unlikely that there is any need for further trials of low-dose aspirin for dementia prevention. If future studies of NSAIDs for dementia prevention are planned, they will need to be cognisant of the safety concerns arising from the existing studies. PMID: 32352165 [PubMed - in process]
Source: Cochrane Database of Systematic Reviews - April 29, 2020 Category: General Medicine Authors: Jordan F, Quinn TJ, McGuinness B, Passmore P, Kelly JP, Tudur Smith C, Murphy K, Devane D Tags: Cochrane Database Syst Rev Source Type: research

Differences in cardiovascular safety with non ‐steroidal anti‐inflammatory drug therapy ‐ a nationwide study in patients with osteoarthritis
This article is protected by copyright. All rights reserved.
Source: Basic and Clinical Pharmacology and Toxicology - November 28, 2018 Category: Drugs & Pharmacology Authors: Carlo Alberto Barcella, Morten Lamberts, Patricia McGettigan, Emil Loldrup Fosb øl, Jesper Lindhardsen, Christian Torp‐Pedersen, Gunnar Hilmar Gislason, Anne‐Marie Schjerning Olsen Tags: Original Article Source Type: research

Drug Safety: Fasinumab Evaluated in Clinical Trials, Plus Celecoxib May Not Pose Increased Heart Attack or Stroke Risk
After an independent review, ongoing clinical trials investigating the safety of fasinumab for treating hip or knee OA will discontinue the use of higher fasinumab doses...
Source: The Rheumatologist - May 15, 2018 Category: Rheumatology Authors: Michele B. Kaufman, PharmD, BCGP Tags: Drug Updates Safety celecoxib Drug Safety fasinumab FDA hip knee Knee Osteoarthritis (OA) Nonsteroidal anti-inflammatory drugs (NSAIDs) Pain Pain Management U.S. Food and Drug Administration (FDA) Source Type: research

Comparative cardiovascular safety of nonsteroidal anti ‐inflammatory drugs in patients with hypertension: a population‐based cohort study
ConclusionsOur results provide important information about the comparative cardiovascular safety of NSAIDs in patients with hypertension.
Source: British Journal of Clinical Pharmacology - March 13, 2018 Category: Drugs & Pharmacology Authors: Yaa ‐Hui Dong, Chia‐Hsuin Chang, Li‐Chiu Wu, Jing‐Shiang Hwang, Sengwee Toh Tags: DRUG SAFETY Source Type: research

Comparative cardiovascular safety of non ‐steroidal anti‐inflammatory drugs in patients with hypertension: a population‐based cohort study
ConclusionsOur results provide important information about the comparative cardiovascular safety of NSAIDs in patients with hypertension.
Source: British Journal of Clinical Pharmacology - February 22, 2018 Category: Drugs & Pharmacology Authors: Yaa ‐Hui Dong, Chia‐Hsuin Chang, Li‐Chiu Wu, Jing‐Shiang Hwang, Sengwee Toh Tags: DRUG SAFETY Source Type: research

Godly gift for arthritis pain
Big Pharma is at it again… Creating and selling a drug that causes thousands of heart attacks and strokes each year. In 2015, the FDA asked drug makers to strengthen their warning labels. Since then, most have listed their dangerous side effects on the bottle. But one manufacturer thought they didn’t have to warn people about their dangerous drug. They marketed their product as a “unique” breakthrough. They even published studies promising it was “safe for long-term use.” 1 The drug is a 7-year-old arthritis drug called Actemra. It’s made by the Swiss pharmaceutical company Roche. ...
Source: Al Sears, MD Natural Remedies - October 5, 2017 Category: Complementary Medicine Authors: Al Sears Tags: Anti-Aging Source Type: news

Celecoxib for rheumatoid arthritis.
CONCLUSIONS: Celecoxib may improve clinical symptoms, alleviate pain and contribute to little or no difference in physical function compared with placebo. Celecoxib was associated with fewer numbers of participant withdrawals. Results for incidence of gastroduodenal ulcers (≥ 3 mm) and short-term serious adverse events were uncertain; however, there were few reported events for either.Celecoxib may slightly improve clinical symptoms compared with tNSAIDs. Results for reduced pain and improved physical function were uncertain. Particpants taking celecoxib had lower incidence of gastroduodenal ulcers (≥ 3 mm) and there w...
Source: Cochrane Database of Systematic Reviews - June 9, 2017 Category: General Medicine Authors: Fidahic M, Jelicic Kadic A, Radic M, Puljak L Tags: Cochrane Database Syst Rev Source Type: research

Nonsteroidal anti-inflammatory drugs and cardiovascular safety - translating pharmacological data into clinical readouts.
Authors: Tacconelli S, Bruno A, Grande R, Ballerini P, Patrignani P Abstract INTRODUCTION: The pharmacological management of pain includes the use of nonsteroidal anti-inflammatory drugs(NSAIDs). They comprise traditional(t) NSAIDs and selective cyclooxygenase(COX)-2 inhibitors (named coxibs). The analgesic and anti-inflammatory effects of NSAIDs are dependent on the extent and duration of COX-2 inhibition in the spinal cord and inflammatory sites. However, the simultaneous inhibition of COX-2 in the vasculature translates into a prothrombotic phenotype and promotes hypertension and heart failure. Areas covered. Th...
Source: Expert Opinion on Drug Safety - June 2, 2017 Category: Drugs & Pharmacology Tags: Expert Opin Drug Saf Source Type: research

Celecoxib ’s Cardiovascular Safety
The selective cyclooxygenase 2 (COX-2) inhibitor celecoxib is no more likely than 2 nonsteroidal anti-inflammatory drugs (NSAIDs) to cause cardiovascular death, nonfatal myocardial infarction, or stroke in patients with coronary disease or other cardiovascular risks.
Source: JAMA - December 27, 2016 Category: Journals (General) Source Type: research

Non ‐steroidal anti‐inflammatory drug‐induced cardiovascular adverse events: a meta‐analysis
Summary What is known and objectiveAlthough non‐steroidal anti‐inflammatory drugs (NSAIDs) have been studied in randomized, controlled trials and meta‐analyses in an effort to determine their cardiovascular (CV) risks, no consensus has been reached. These studies continue to raise questions, including whether cyclooxygenase‐2 (COX‐2) selectivity plays a role in conferring CV risk. We performed a meta‐analysis of current literature to determine whether COX‐2 selectivity leads to an increased CV risk. MethodsWe utilized randomized, controlled trials and prospective cohort studies. We selected eight NSAIDs based...
Source: Journal of Clinical Pharmacy and Therapeutics - November 30, 2016 Category: Drugs & Pharmacology Authors: B. R. Gunter, K. A. Butler, R. L. Wallace, S. M. Smith, S. Harirforoosh Tags: Review Article Source Type: research

Celebrex study shows less risk to heart health than expected
Researchers spend a decade studying Celebrex, an arthritis drug, to see if it causes heart problems. A similar drug was removed from the market in 2004, as it increased the risk of heart attack and stroke. Dr. Jon LaPook reports.
Source: Health News: CBSNews.com - November 15, 2016 Category: Consumer Health News Source Type: news

Celebrex Is No Riskier For Heart Than Other Arthritis Drugs, Study Finds
NEW ORLEANS (AP) — A new study gives some reassurance to arthritis sufferers who want pain relief but are worried about side effects. It finds that Celebrex, a drug similar to ones withdrawn 12 years ago for safety reasons, is no riskier for the heart than some other prescription pain pills that are much tougher on the stomach. “We do not want patients to suffer with pain and we need to know what is safe to give them,” said Dr. Steven Nissen, the Cleveland Clinic’s heart chief, who led the study. Fear that Celebrex would be worse than alternatives proved unfounded, and “on almost every endpoint it...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - November 14, 2016 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health News Arthritis Celebrex Source Type: news

Pages: 1  2